Efficacy and safety of anlotinib combined with <sup>125</sup>I seed implantation for iodine-refractory thyroid cancer.

It is also possible that a true OS benefit from the combination might emerge with longer observation; indeed, we observed a numerical advantage in median OS for Group C (43.1 months) versus the others (~22.3 months), although this difference did not reach statistical significance in our sample.

also in 111,027 other papers